{"id":51163,"date":"2025-12-17T21:25:34","date_gmt":"2025-12-17T13:25:34","guid":{"rendered":"https:\/\/flcube.com\/?p=51163"},"modified":"2025-12-17T21:25:35","modified_gmt":"2025-12-17T13:25:35","slug":"adagenes-muzastotug-wins-fda-fast-track-for-ctla-4-cancer-combo","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=51163","title":{"rendered":"Adagene&#8217;s Muzastotug Wins FDA Fast Track for CTLA-4 Cancer Combo"},"content":{"rendered":"\n<p><strong>Adagene Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/ADAG:NASDAQ\">NASDAQ: ADAG<\/a>) announced that the U.S. <strong>Food and Drug Administration (FDA)<\/strong> granted <strong>Fast Track designation<\/strong> to <strong>Muzastotug (ADG126)<\/strong>, its next\u2011generation masked anti\u2011CTLA\u20114 SAFEbody, in combination with <strong>KEYTRUDA (pembrolizumab)<\/strong> for cancer treatment. The designation accelerates review of a therapy designed to <strong>selectively inhibit regulatory T cells (Tregs)<\/strong> within the tumor microenvironment while improving safety and expanding the therapeutic index versus existing CTLA\u20114 inhibitors.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-amp-drug-profile\">Regulatory &amp; Drug Profile<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>Designation<\/strong><\/td><td>FDA Fast Track<\/td><\/tr><tr><td><strong>Drug<\/strong><\/td><td>Muzastotug (ADG126)<\/td><\/tr><tr><td><strong>Combination<\/strong><\/td><td>KEYTRUDA (pembrolizumab)<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>Masked anti\u2011CTLA\u20114 SAFEbody; selectively inhibits Tregs mediated by CTLA\u20114<\/td><\/tr><tr><td><strong>Innovation<\/strong><\/td><td>Enhances anti\u2011tumor efficacy while significantly improving safety<\/td><\/tr><tr><td><strong>Market Context<\/strong><\/td><td><strong>First masked CTLA\u20114 SAFEbody<\/strong> to receive Fast Track; addresses toxicity limitations of ipilimumab<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-significance\">Clinical Significance<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Selective Targeting:<\/strong> Muzastotug\u2019s <strong>SAFEbody technology<\/strong> enables tumor\u2011localized CTLA\u20114 blockade, reducing systemic immune activation and associated adverse events<\/li>\n\n\n\n<li><strong>Therapeutic Index:<\/strong> Expands the <strong>treatment window<\/strong> for CTLA\u20114 inhibition, potentially enabling higher dosing and improved efficacy<\/li>\n\n\n\n<li><strong>Combination Rationale:<\/strong> Synergizes with PD\u20111 inhibition (KEYTRUDA) to overcome <strong>checkpoint resistance<\/strong> in solid tumors<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity\">Market Opportunity<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>Value<\/th><th>Context<\/th><\/tr><\/thead><tbody><tr><td><strong>Global CTLA\u20114 Market<\/strong><\/td><td><strong>$7\u20119\u202fbillion<\/strong> (2025)<\/td><td>Dominated by ipilimumab (Yervoy)<\/td><\/tr><tr><td><strong>Next\u2011Gen CTLA\u20114 Pipeline<\/strong><\/td><td>Several masked\/bispecific agents in Phase\u202f1\/2<\/td><td>Muzastotug leads with <strong>Fast Track designation<\/strong><\/td><\/tr><tr><td><strong>Combination Therapy Market<\/strong><\/td><td><strong>$15\u201120\u202fbillion<\/strong> (PD\u20111\/CTLA\u20114 combos)<\/td><td>High unmet need for safer, more effective regimens<\/td><\/tr><tr><td><strong>Peak Sales Potential<\/strong><\/td><td><strong>$1\u20112\u202fbillion<\/strong> (global estimate)<\/td><td>If approved in melanoma, NSCLC, and other solid tumors<\/td><\/tr><tr><td><strong>Competitive Edge<\/strong><\/td><td><strong>Tumor\u2011selective activation<\/strong> reduces irAEs vs. first\u2011gen CTLA\u20114 inhibitors<\/td><td>Differentiated safety profile supports broader adoption<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>For Adagene:<\/strong> <strong>Fast Track designation<\/strong> validates <strong>SAFEbody platform<\/strong>; accelerates clinical development timeline; positions company for <strong>potential partnering<\/strong> in ex\u2011China markets; monetization pathway via <strong>licensing or co\u2011development<\/strong>.<\/li>\n\n\n\n<li><strong>For CTLA\u20114 Class:<\/strong> <strong>Muzastotug\u2019s tumor\u2011localized mechanism<\/strong> could <strong>revitalize CTLA\u20114 use<\/strong> in combinations; addresses <strong>ipilimumab toxicity<\/strong> that limits adoption; potential for <strong>first\u2011line use<\/strong> in immunotherapy\u2011na\u00efve patients.<\/li>\n\n\n\n<li><strong>For Market:<\/strong> Demonstrates <strong>China\u2019s biotech innovation<\/strong> in immuno\u2011oncology; <strong>masked antibody technology<\/strong> is emerging as a key trend; <strong>FDA Fast Track<\/strong> signals strong clinical rationale and unmet need.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding Muzastotug\u2019s clinical development timeline, market potential, and partnership opportunities. Actual results may differ due to clinical risks, competitive responses, or regulatory feedback.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Adagene Inc. (NASDAQ: ADAG) announced that the U.S. Food and Drug Administration (FDA) granted Fast&#8230;<\/p>\n","protected":false},"author":1,"featured_media":51165,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[180,973],"class_list":["post-51163","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-adagene","tag-nasdaq-adag"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Adagene&#039;s Muzastotug Wins FDA Fast Track for CTLA-4 Cancer Combo - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Adagene Inc. (NASDAQ: ADAG) announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to Muzastotug (ADG126), its next\u2011generation masked anti\u2011CTLA\u20114 SAFEbody, in combination with KEYTRUDA (pembrolizumab) for cancer treatment. The designation accelerates review of a therapy designed to selectively inhibit regulatory T cells (Tregs) within the tumor microenvironment while improving safety and expanding the therapeutic index versus existing CTLA\u20114 inhibitors.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=51163\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Adagene&#039;s Muzastotug Wins FDA Fast Track for CTLA-4 Cancer Combo\" \/>\n<meta property=\"og:description\" content=\"Adagene Inc. (NASDAQ: ADAG) announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to Muzastotug (ADG126), its next\u2011generation masked anti\u2011CTLA\u20114 SAFEbody, in combination with KEYTRUDA (pembrolizumab) for cancer treatment. The designation accelerates review of a therapy designed to selectively inhibit regulatory T cells (Tregs) within the tumor microenvironment while improving safety and expanding the therapeutic index versus existing CTLA\u20114 inhibitors.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=51163\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-17T13:25:34+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-17T13:25:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1703.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51163#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51163\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Adagene&#8217;s Muzastotug Wins FDA Fast Track for CTLA-4 Cancer Combo\",\"datePublished\":\"2025-12-17T13:25:34+00:00\",\"dateModified\":\"2025-12-17T13:25:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51163\"},\"wordCount\":383,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51163#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1703.webp\",\"keywords\":[\"Adagene\",\"NASDAQ: ADAG\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=51163#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51163\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=51163\",\"name\":\"Adagene's Muzastotug Wins FDA Fast Track for CTLA-4 Cancer Combo - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51163#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51163#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1703.webp\",\"datePublished\":\"2025-12-17T13:25:34+00:00\",\"dateModified\":\"2025-12-17T13:25:35+00:00\",\"description\":\"Adagene Inc. (NASDAQ: ADAG) announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to Muzastotug (ADG126), its next\u2011generation masked anti\u2011CTLA\u20114 SAFEbody, in combination with KEYTRUDA (pembrolizumab) for cancer treatment. The designation accelerates review of a therapy designed to selectively inhibit regulatory T cells (Tregs) within the tumor microenvironment while improving safety and expanding the therapeutic index versus existing CTLA\u20114 inhibitors.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51163#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=51163\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51163#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1703.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1703.webp\",\"width\":1080,\"height\":608,\"caption\":\"Adagene's Muzastotug Wins FDA Fast Track for CTLA-4 Cancer Combo\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51163#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Adagene&#8217;s Muzastotug Wins FDA Fast Track for CTLA-4 Cancer Combo\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Adagene's Muzastotug Wins FDA Fast Track for CTLA-4 Cancer Combo - Insight, China&#039;s Pharmaceutical Industry","description":"Adagene Inc. (NASDAQ: ADAG) announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to Muzastotug (ADG126), its next\u2011generation masked anti\u2011CTLA\u20114 SAFEbody, in combination with KEYTRUDA (pembrolizumab) for cancer treatment. The designation accelerates review of a therapy designed to selectively inhibit regulatory T cells (Tregs) within the tumor microenvironment while improving safety and expanding the therapeutic index versus existing CTLA\u20114 inhibitors.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=51163","og_locale":"en_US","og_type":"article","og_title":"Adagene's Muzastotug Wins FDA Fast Track for CTLA-4 Cancer Combo","og_description":"Adagene Inc. (NASDAQ: ADAG) announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to Muzastotug (ADG126), its next\u2011generation masked anti\u2011CTLA\u20114 SAFEbody, in combination with KEYTRUDA (pembrolizumab) for cancer treatment. The designation accelerates review of a therapy designed to selectively inhibit regulatory T cells (Tregs) within the tumor microenvironment while improving safety and expanding the therapeutic index versus existing CTLA\u20114 inhibitors.","og_url":"https:\/\/flcube.com\/?p=51163","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-12-17T13:25:34+00:00","article_modified_time":"2025-12-17T13:25:35+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1703.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=51163#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=51163"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Adagene&#8217;s Muzastotug Wins FDA Fast Track for CTLA-4 Cancer Combo","datePublished":"2025-12-17T13:25:34+00:00","dateModified":"2025-12-17T13:25:35+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=51163"},"wordCount":383,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=51163#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1703.webp","keywords":["Adagene","NASDAQ: ADAG"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=51163#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=51163","url":"https:\/\/flcube.com\/?p=51163","name":"Adagene's Muzastotug Wins FDA Fast Track for CTLA-4 Cancer Combo - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=51163#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=51163#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1703.webp","datePublished":"2025-12-17T13:25:34+00:00","dateModified":"2025-12-17T13:25:35+00:00","description":"Adagene Inc. (NASDAQ: ADAG) announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to Muzastotug (ADG126), its next\u2011generation masked anti\u2011CTLA\u20114 SAFEbody, in combination with KEYTRUDA (pembrolizumab) for cancer treatment. The designation accelerates review of a therapy designed to selectively inhibit regulatory T cells (Tregs) within the tumor microenvironment while improving safety and expanding the therapeutic index versus existing CTLA\u20114 inhibitors.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=51163#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=51163"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=51163#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1703.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1703.webp","width":1080,"height":608,"caption":"Adagene's Muzastotug Wins FDA Fast Track for CTLA-4 Cancer Combo"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=51163#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Adagene&#8217;s Muzastotug Wins FDA Fast Track for CTLA-4 Cancer Combo"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1703.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/51163","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=51163"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/51163\/revisions"}],"predecessor-version":[{"id":51166,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/51163\/revisions\/51166"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/51165"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=51163"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=51163"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=51163"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}